 |
Sanofi says MS treatment reduced relapse rateSanofi said on Friday a trial of its multiple-sclerosis treatment teriflunomide found that a daily dose of the drug reduced the rate of relapse by 36 per cent compared with a placebo. Teriflunomide, marketed as Aubagio, is one of the two m More… |
Friday 19 April 2024
